New Science Ventures

New Science Ventures (NSV) is a venture capital firm specializing in investments within the life sciences and information technology sectors. The firm seeks companies that employ novel scientific approaches to address significant unmet needs, aiming to create substantial improvements in performance. NSV manages over $900 million in assets under management, based on original committed capital, and has invested in more than 80 companies across the United States, Europe, India, and China. The firm's investment strategy emphasizes identifying companies targeting large, global markets exceeding $1 billion, with differentiated value propositions and strong management teams. NSV focuses on fundamental, science-based innovation with robust intellectual property protection, often taking contrarian views and building teams that fit the companies' stages of development. The firm is patient, supporting its portfolio companies through value inflection points. NSV's portfolio includes companies such as NorthSea Therapeutics, Ventyx Biosciences, Phase Four, Novadip Biosciences, and Sagence AI, reflecting its commitment to transformative science and technology in healthcare and other sectors.

Founded in 2004, NSV has offices in Greenwich, Connecticut, and London, United Kingdom. The firm's team comprises experienced professionals with backgrounds in life sciences and information technology, bringing a wealth of investment experience and board expertise across the US and Europe. The team includes Managing Partner Somu Subramaniam, Partner Tom Lavin, Partner and Senior Advisor Jean-Pierre Bizet, Partner and Senior Advisor Raju Mohan, and Partner Andrew Abrams. The finance team is led by Partner and Chief Financial Officer Brenda Marex. NSV's approach combines deep scientific understanding with strategic investment to foster innovation and growth in its portfolio companies.

NSV's investment philosophy centers on leveraging breakthrough science to create extraordinary value. The firm focuses on sectors with strong, decades-long tailwinds, where it has direct experience and can leverage its extensive external networks to create value. This approach has led to successful investments in companies like NorthSea Therapeutics, which is developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases, and Ventyx Biosciences, focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. Other notable investments include Phase Four, a leader in advanced in-space propulsion design and manufacturing, Novadip Biosciences, specializing in regenerative medicine, and Sagence AI, which unveiled a groundbreaking advanced analog in-memory compute architecture addressing power, performance, price, and environmental sustainability in AI inferencing. These investments underscore NSV's commitment to supporting companies that are at the forefront of scientific and technological innovation, aiming to address significant global challenges and create substantial value.